This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Rebamipide is a gastroprotective agent used in combination with other similar therapies (e.g. proton pump inhibitors) to treat gastritis and protect the gastric mucosa.
- Generic Name
- Rebamipide
- DrugBank Accession Number
- DB11656
- Background
Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Rebamipide (DB11656)
- Weight
- Average: 370.79
Monoisotopic: 370.0720347 - Chemical Formula
- C19H15ClN2O4
- Synonyms
- Rebamipida
- Rebamipide
- Rébamipide
- Rebamipidum
- External IDs
- OPC 12759
- OPC-12759
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in treatment of Gastric ulcer •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Take with or without food. Food does not impact the bioavailability of rebamipide.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Mucosta
Categories
- ATC Codes
- A02BX14 — Rebamipide
- Drug Categories
- Alimentary Tract and Metabolism
- Amino Acids
- Amino Acids, Peptides, and Proteins
- Anti-Ulcer Agents
- Antioxidants
- Biological Factors
- Compounds used in a research, industrial, or household setting
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Enzyme Inhibitors
- Gastrointestinal Agents
- Heterocyclic Compounds, Fused-Ring
- Protective Agents
- Quinolines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as hippuric acids. These are compounds containing hippuric acid, which consists of a of a benzoyl group linked to the N-terminal of a glycine.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Hippuric acids
- Alternative Parents
- N-acyl-alpha amino acids / Quinolones and derivatives / Hydroxyquinolines / 4-halobenzoic acids and derivatives / Benzoyl derivatives / Hydroxypyridines / Chlorobenzenes / Aryl chlorides / Heteroaromatic compounds / Secondary carboxylic acid amides show 9 more
- Substituents
- 4-halobenzoic acid or derivatives / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzoyl / Carbonyl group / Carboxamide group / Carboxylic acid show 25 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- LR583V32ZR
- CAS number
- 90098-04-7
- InChI Key
- ALLWOAVDORUJLA-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H15ClN2O4/c20-13-7-5-11(6-8-13)18(24)22-16(19(25)26)9-12-10-17(23)21-15-4-2-1-3-14(12)15/h1-8,10,16H,9H2,(H,21,23)(H,22,24)(H,25,26)
- IUPAC Name
- 2-[(4-chlorophenyl)formamido]-3-(2-oxo-1,2-dihydroquinolin-4-yl)propanoic acid
- SMILES
- OC(=O)C(CC1=CC(=O)NC2=C1C=CC=C2)NC(=O)C1=CC=C(Cl)C=C1
References
- General References
- BPOM Drug Information: Rebamipide for oral use [Link]
- External Links
- PubChem Compound
- 5042
- PubChem Substance
- 347828027
- ChemSpider
- 4866
- ChEBI
- 93814
- ChEMBL
- CHEMBL1697771
- Wikipedia
- Rebamipide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Dry Eye Syndrome (DES) / Sjögren's Syndrome (SS) 1 4 Completed Treatment Gastric Ulcer 2 4 Completed Treatment Gastritis 1 4 Completed Treatment Gastritis Acute / Gastritis Chronic 1 4 Completed Treatment Gastroesophageal Reflux 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet 100 mg Tablet, film coated Oral Granule Tablet, film coated Oral 100 mg Tablet, coated Oral 100 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0103 mg/mL ALOGPS logP 2.32 ALOGPS logP 2.76 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 3.52 Chemaxon pKa (Strongest Basic) -1.1 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 95.5 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 98.5 m3·mol-1 Chemaxon Polarizability 36.82 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 181.46217 predictedDeepCCS 1.0 (2019) [M+H]+ 183.82018 predictedDeepCCS 1.0 (2019) [M+Na]+ 190.87321 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 20:37 / Updated at May 21, 2021 10:22